Drug intelligence / Profile preview

GLYNx

Development stage: Preclinical
Lead developer: Neurobio.ai
Modality: Small Molecules

Overview

GLYNx is a preclinical drug discovery program developed by NeuroBio.ai, targeting Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The program utilizes the proprietary GLYNx AI platform, which leverages graph neural networks and explainable artificial intelligence to identify novel therapeutic targets and optimize small molecule candidates. Currently in the discovery phase, the program aims to address the underlying biological drivers of neurodegeneration. While the specific molecular targets remain proprietary, the platform is designed to navigate the complex pathology of ALS and FTD to find high-affinity drug-target pairs.

Other names: GLYNx ALS/FTD programGLYNx-NeuroBio.ai-ALS (Amyotrophic Lateral Sclerosis)-Frontotemporal Dementia

Beyond the preview

Go deeper on GLYNx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLYNx.

Explore the full profile